In patients with type 2 diabetes mellitus, higher heart rate (HR) is associated with an increased risk of death and cardiovascular complications 1 . Sodium-glucose cotransporter 2 inhibitors were approved as novel antihyperglycemic agents, and are known to decrease blood glucose levels without affecting HR. However, to the best of our knowledge, no detailed analysis has been undertaken in patients stratified by baseline HR. In the present study, we evaluated the changes in HR after treatment with the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus.
Three placebo-controlled, double-blind studies of luseogliflozin, including two dose-finding phase 2 studies and a phase 3 randomized study, were merged in this pooled analysis. These studies are registered at the Japan Pharmaceutical Information Center (identifier: JapicCTI-090908, JapicCTI-101191 and JapicCTI-111661) [2] [3] [4] . The major inclusion criteria were as follows: Japanese patients with type 2 diabetes mellitus receiving diet and exercise therapy alone, age ≥20 years and with glycated hemoglobin levels ≥6.9% to ≤10.5%. The changes in HR from baseline to 12 weeks after treatment with luseogliflozin were assessed by using a paired t-test and an analysis of covariance with baseline as a covariate at a two-sided a level of 0.05. Other clinical parameters were similarly measured using a paired t-test. Missing data were not imputed, and all analyses were carried out using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Of 501 patients enrolled in the three studies, 489 were included in this pooled analysis. The patients were divided into three groups as follows: placebo, n = 183; luseogliflozin 2.5 mg, n = 194; luseogliflozin 5.0 mg, n = 112. The mean -standard deviation age was 58.3 -10.0, 58.2 -9.6 and 56.8 -10.3 years; glycated hemoglobin levels were 7.98 -0.74%, 8.09 -0.86% and 8.02 -0.87%; and number (percentage) of male patients was 132 (72.1), 131 (67.5) and 83 (74.1), respectively. Table 1 shows the changes in clinical parameters from baseline to 12 weeks when the patients were stratified by baseline HR. Treatment with both luseogliflozin 2.5 mg and 5.0 mg showed significant reductions in HR from baseline in patients with HR >70 b.p.m. Detailed stratification of patients with HR >70 b.p.m. showed that luseogliflozin 2.5 mg significantly decreased the HR in all subgroups compared with the baseline HR, whereas luseogliflozin 5.0 mg significantly decreased the HR only in patients with baseline HR >80 b.p.m. In addition, the decrease with 2.5 mg, but not 5.0 mg, luseogliflozin was also significant compared with the placebo (P = 0.016). Although the reason for this result is unknown, it is to be noted that high-density lipoprotein cholesterol and blood urea nitrogen levels were significantly increased from baseline in patients with lower baseline HR (<70 b.p.m.) in the luseogliflozin 2.5 mg group. Additionally, there was no correlation between the change in each parameter from baseline in Table 1 and the change in HR from baseline.
The incidence of adverse events among patients with HR ≥70 b.p.m. and HR <70 b.p.m. at baseline was 40.4% and 42.3%, respectively, in the luseogliflozin 2.5 mg group, and 50.0% and 34.8%, respectively, in the luseogliflozin 5.0 mg group. Although the incidence of adverse events was higher in the 5.0 mg group with higher baseline HR, there were no remarkable adverse events in the higher dose group. Throughout the studies, luseogliflozin was well tolerated. It is suggested that luseogliflozin can effectively decrease the HR in patients with higher baseline HR. Some patients with type 2 diabetes mellitus have elevated central sympathetic activity, which is exacerbated by a malfunction of the negative feedback mechanism as a result of decreased sensitivity of baroreceptor reflexes 5, 6 . This results in elevation of peripheral sympathetic activity in the heart, leading to an increase in resting HR. These results suggest that luseogliflozin could calm elevated central sympathetic activity, while having no such effect in patients with normal central sympathetic activity. DISCLOSURE YS received consulting and/or speaker's fees from Eli Lilly Japan K.K., Sanofi K.K., Novo Nordisk Pharma Inc., Glaxo-SmithKline, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., BD, Nippon 
